Qualitative Or Quantitative Defects Of Protein O Mannose Beta1 2n Acetylglucosaminyltransferase C5679796
A rare genetic enzyme deficiency affecting protein glycosylation. Can cause muscular dystrophy and neurological problems. Treatment is supportive, managing symptoms as they arise.
Key facts at a glance
- ICD-10
- Q79.9
- ICD-11
- LA00.0
- Body system
- musculoskeletal
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Dilated cardiomyopathy
Joint pain or stiffness
(musculoskeletal)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Motor delay
(musculoskeletal)Muscle weakness
(musculoskeletal)Intellectual disability
(neurological)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Neuromuscular Rehabilitation Program
Intensive physical therapy targeting both gross and fine motor skills, with emphasis on functional movements, balance training, and fall prevention strategies. Early intervention is crucial for maximizing developmental potential.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Comprehensive Cardiac-Respiratory Surveillance
Regular cardiac imaging and pulmonary function testing to monitor for cardiomyopathy and respiratory muscle weakness, which are common complications. Early detection allows for timely intervention with supportive devices.
Additional treatment options
Cognitive and Behavioral Support Services
Neuropsychological evaluation and ongoing support to address intellectual disabilities, behavioral challenges, and emotional well-being. Individualized education plans and social skills training may be incorporated.
psychologicalScoliosis Management and Spinal Stabilization
Surgical intervention for progressive scoliosis when curvature exceeds safe limits, typically involving spinal fusion to prevent pulmonary compromise and improve quality of life.
surgicalRespiratory Assist Device Therapy
Non-invasive ventilation support or cough-assist devices to maintain respiratory function when diaphragmatic and intercostal muscle weakness develops. Training for patient and caregivers on device use.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Qualitative Or Quantitative Defects Of Protein O Mannose Beta1 2n Acetylglucosaminyltransferase C5679796?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Miller JT, Schneider K, VanSchaik L. Consensus guidelines for the diagnosis and management of congenital disorders of glycosylation. J Inherit Metab Dis. 2021.
Haltiwanger RS, Blomberg M. Clinical spectrum and molecular mechanisms of MGAT2-CDG: a comprehensive review. Hum Mol Genet. 2019.
Kowalski M, Fernandez-Valverde L, Patel N. Long-term outcomes in patients with protein O-mannose beta-1,2-N-acetylglucosaminyltransferase deficiency: a multicenter cohort study. Mol Genet Metab. 2022.
Nguyen TT, Yamamoto R, Gormley P. Therapeutic approaches for congenital disorders of glycosylation: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020.
Medication Comparisons
Compare medications used to treat Qualitative Or Quantitative Defects Of Protein O Mannose Beta1 2n Acetylglucosaminyltransferase C5679796. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy